Related Experiment Video
Updated: Apr 10, 2026
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Systemic effects of type 2 diabetes therapies: an integrated perspective on the cardio-renal- cerebral-metabolic axis
Lin Zhu1, Chen Chen2, Feng Lu1
1University Town Hospital, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Department of Endocrinology, Jinan, China.
Abstract:
Type 2 diabetes (T2D) has been treated as an underlying disease-hyperglycemia, but is instead a systemic disease-mediating the network of neural, endocrine, and immune signaling. In recent years, the concept of the cardio-renal-cerebral-metabolic axis has provided an integrative pathophysiological framework for understanding the multisystem complications of diabetes. From this perspective, the present review systematically elucidates the substantial evolution in modern T2D therapeutic strategies from simple glycemic control to comprehensive multi-organ protection. The primary pathology is that high insulin resistance and chronic metabolic disturbances trigger oxidative stress and inflammation, which in turn drive a vicious cycle in the heart, kidneys, and brain. In this review, we demonstrate that new drugs based on sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and mineralocorticoid receptor antagonists, which are capable of lowering glucose to promote efficient glycemic control, decrease cardiovascular events, lower the risk of renal disease, and demonstrate neuroprotective properties as the key to organ protection. Additionally, non-pharmacological interventions and new treatments can be combined as a multi-targeting, multilayer management system. Furthermore, greater knowledge and integration of the cardio-renal-cerebral-metabolic axis could signal a shift toward precision medicine to stabilize the network's homeostasis and improve long-term patient outcomes.
Insights
Type 2 diabetes is a systemic disease impacting multiple organs. New therapies focus on organ protection beyond blood sugar control, improving patient outcomes.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Medicine
- Nephrology
- Neurology
- Pharmacology
Background:
- Type 2 diabetes (T2D) is increasingly recognized as a systemic disease affecting neural, endocrine, and immune signaling networks, not just hyperglycemia.
- The cardio-renal-cerebral-metabolic axis provides a framework for understanding T2D's multisystem complications, including heart, kidney, and brain involvement.
- Chronic metabolic disturbances and insulin resistance in T2D promote oxidative stress and inflammation, creating a detrimental cycle across vital organs.
Purpose of the Study:
- To review the evolution of T2D therapeutic strategies from solely glycemic control to comprehensive multi-organ protection.
- To elucidate the role of novel pharmacological agents in mitigating T2D-related organ damage.
- To highlight the potential of integrating the cardio-renal-cerebral-metabolic axis concept for precision medicine approaches in T2D management.
Main Methods:
- Systematic review of modern T2D therapeutic strategies.
- Analysis of the pathophysiological mechanisms linking T2D to cardiovascular, renal, and neurological complications.
- Evaluation of the organ-protective effects of specific drug classes, including SGLT2 inhibitors, GLP-1 receptor agonists, and MRAs.
Main Results:
- Newer drug classes like sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists demonstrate significant benefits beyond glycemic control.
- These agents reduce cardiovascular events, slow renal disease progression, and offer neuroprotective properties, key to comprehensive organ protection.
- Mineralocorticoid receptor antagonists (MRAs) also contribute to multi-organ protection in the context of T2D.
Conclusions:
- Modern T2D management requires a shift towards multi-organ protection, integrating novel pharmacotherapies with non-pharmacological interventions.
- Understanding and applying the cardio-renal-cerebral-metabolic axis framework can guide precision medicine strategies for T2D.
- A multi-targeting, multilayer management system is essential for stabilizing metabolic homeostasis and improving long-term patient outcomes in T2D.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:36Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
01:22Diabetes Mellitus: Type 2 and Gestational
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System